Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

Research progress of cyclin-dependent kinase 4 and 6 in the treatment of breast cancer

YANG Fang, GUAN Xiaoxiang.   

  1. Department of Oncology, Medical School of Nanjing University, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, China
  • Received:2014-11-11 Revised:2015-03-19 Online:2015-07-31 Published:2015-07-31

Abstract: Cellular proliferation, growth, and division are tightly controlled by the cell-cycle regulatory machinery. Recently, cyclin-dependent kinase 4 and 6(CDK4/6) inhibitors were identified to be useful in breast cancer patients with positive estrogen receptor or amplified HER-2, whereas the role remains controversial in triple-negative breast cancer. It is of great importance to investigate the predictive biomarkers for identifying which subgroup of breast cancer patients would mostly benefit from such treatment. Moreover, tumor suppressor retinoblastoma(Rb) plays a pivotal importance in breast cancer, and cyclin D-CDK4/6-Rb pathway, governing the cell cycle restriction point in breast cancer, is a potential target for anticancer therapy. In this article, we review the preclinical and clinical data and describe the future development on the role of CDK4/6 inhibitors in breast cancer.

No related articles found!
Viewed
Full text
347
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 347

  From Others local
  Times 30 317
  Rate 9% 91%

Abstract
193
Just accepted Online first Issue
0 0 193
  From Others
  Times 193
  Rate 100%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
No Suggested Reading articles found!